A specific advanced prostate cancer test becomes standard for some government patients

The US government committed to buying a specific genomic test for prostate cancer for the next five years. This means patients in some government healthcare systems will now receive this advanced diagnostic.

For patients in government healthcare systems, this means access to a specific genomic test that helps predict how aggressive their prostate cancer is. Doctors can use this information to make more precise treatment plans, avoiding unnecessary procedures for some and ensuring aggressive treatment for others.